Vanessa M Scarfone

Ms. Vanessa M Scarfone

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Neuron
Verified
Journal Article
Closed access
EAEdsel M. Abud
Edsel M. Abud
RRRicardo N. Ramirez
Ricardo N. Ramirez
EMEric S. Martinez
Eric S. Martinez
LHLuke M. Healy
Luke M. Healy
CNCecilia H.H. Nguyen
Cecilia H.H. Nguyen
MBMathew Blurton-Jones
Mathew Blurton-Jones

3 September 2008 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MKMichael G. Kharas
Michael G. Kharas
MJMatthew R. Janes
Matthew R. Janes
VSVanessa M Scarfone
Vanessa M Scarfone
MLMichael B. Lilly
Michael B. Lilly
ZKZachary A. Knight
Zachary A. Knight
DFDavid A. Fruman
David A. Fruman
Some cases of pre–B cell acute lymphoblastic leukemia (pre–B-ALL) are caused by the Philadelphia (Ph) chromosome–encoded BCR-ABL oncogene, and these tend to have a poor prognosis. Inhibitors of the PI3K/AKT pathway reduce BCR-ABL–mediated transformation in vitro; however, the specific PI3K isoforms involved are poorly defined. Using a murine model of Ph+ pre–B-ALL, we found that deletion of both Pik3r1 and Pik3r2, genes encoding class IA PI3K regulatory isoforms, severely impaired transformation. BCR-ABL–dependent pre/pro-B cell lines could be established at low frequency from progenitors that lacked these genes, but the cells were smaller, proliferated more slowly, and failed to cause leukemia in vivo. These cell lines displayed nearly undetectable PI3K signaling function and were resistant to the PI3K inhibitor wortmannin. However, they maintained activation of mammalian target of rapamycin (mTOR) and were more sensitive to rapamycin. Treatment with rapamycin caused feedback activation of AKT in WT cell lines but not PI3K-deficient lines. A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre–B-ALL and human CD19+CD34+ Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib. Our findings provide mechanistic insights into PI3K dependency in oncogenic networks and provide a rationale for targeting class IA PI3K, alone or together with mTOR, in the treatment of Ph+ ALL.

1 March 2019 in Stem Cell Reports
Verified
Journal Article
Open access
TFTannaz Faal
Tannaz Faal
DPDuc T.T. Phan
Duc T.T. Phan
HDHayk Davtyan
Hayk Davtyan
VSVanessa M Scarfone
Vanessa M Scarfone
EVErika Varady
Erika Varady
MIMatthew A. Inlay
Matthew A. Inlay
In the CNS, perivascular cells ("pericytes") associate with endothelial cells to mediate the formation of tight junctions essential to the function of the blood-brain barrier (BBB). The BBB protects the CNS by regulating the flow of nutrients and toxins into and out of the brain. BBB dysfunction has been implicated in the progression of Alzheimer's disease (AD), but the role of pericytes in BBB dysfunction in AD is not well understood. In the developing embryo, CNS pericytes originate from two sources: mesoderm and neural crest. In this study, we report two protocols using mesoderm or neural crest intermediates, to generate brain-specific pericyte-like cells from induced pluripotent stem cell (iPSC) lines created from healthy and AD patients. iPSC-derived pericytes display stable expression of pericyte surface markers and brain-specific genes and are functionally capable of increasing vascular tube formation and endothelial barrier properties.

15 November 2013 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
XDXavier Dervillez
Xavier Dervillez
HQHuma Qureshi
Huma Qureshi
ACAziz A Chentoufi
Aziz A Chentoufi
AKArif A Khan
Arif A Khan
EKElizabeth Kritzer
Elizabeth Kritzer
LBLBACHIR BENMOHAMED
LBACHIR BENMOHAMED
Evidence from C57BL/6 mice suggests that CD8+ T cells, specific to the immunodominant HSV-1 glycoprotein B (gB) H-2b–restricted epitope (gB498–505), protect against ocular herpes infection and disease. However, the possible role of CD8+ T cells, specific to HLA-restricted gB epitopes, in protective immunity seen in HSV-1–seropositive asymptomatic (ASYMP) healthy individuals (who have never had clinical herpes) remains to be determined. In this study, we used multiple prediction algorithms to identify 10 potential HLA-A*02:01–restricted CD8+ T cell epitopes from the HSV-1 gB amino acid sequence. Six of these epitopes exhibited high-affinity binding to HLA-A*02:01 molecules. In 10 sequentially studied HLA-A*02:01–positive, HSV-1–seropositive ASYMP individuals, the most frequent, robust, and polyfunctional CD8+ T cell responses, as assessed by a combination of tetramer, IFN-γ-ELISPOT, CFSE proliferation, CD107a/b cytotoxic degranulation, and multiplex cytokine assays, were directed mainly against epitopes gB342–350 and gB561–569. In contrast, in 10 HLA-A*02:01–positive, HSV-1–seropositive symptomatic (SYMP) individuals (with a history of numerous episodes of recurrent clinical herpes disease) frequent, but less robust, CD8+ T cell responses were directed mainly against nonoverlapping epitopes (gB183–191 and gB441–449). ASYMP individuals had a significantly higher proportion of HSV-gB–specific CD8+ T cells expressing CD107a/b degranulation marker and producing effector cytokines IL-2, IFN-γ, and TNF-α than did SYMP individuals. Moreover, immunization of a novel herpes-susceptible HLA-A*02:01 transgenic mouse model with ASYMP epitopes, but not with SYMP epitopes, induced strong CD8+ T cell–dependent protective immunity against ocular herpes infection and disease. These findings should guide the development of a safe and effective T cell–based herpes vaccine.

5 September 2006 in Blood
Verified
Journal Article
Open access
PDF file
MKMichael G. Kharas
Michael G. Kharas
IYIsharat Yusuf
Isharat Yusuf
VSVanessa M Scarfone
Vanessa M Scarfone
VYVincent W. Yang
Vincent W. Yang
JSJulia A. Segre
Julia A. Segre
DFDavid A. Fruman
David A. Fruman
Genes that are strongly repressed after B-cell activation are candidates for being inactivated, mutated, or repressed in B-cell malignancies. Krüppel-like factor 4 (Klf4), a gene down-regulated in activated murine B cells, is expressed at low levels in several types of human B-cell lineage lymphomas and leukemias. The human KLF4 gene has been identified as a tumor suppressor gene in colon and gastric cancer; in concordance with this, overexpression of KLF4 can suppress proliferation in several epithelial cell types. Here we investigate the effects of KLF4 on pro/pre–B-cell transformation by v-Abl and BCR-ABL, oncogenes that cause leukemia in mice and humans. We show that overexpression of KLF4 induces arrest and apoptosis in the G1 phase of the cell cycle. KLF4-mediated death, but not cell-cycle arrest, can be rescued by Bcl-XL overexpression. Transformed pro/pre-B cells expressing KLF4 display increased expression of p21CIP and decreased expression of c-Myc and cyclin D2. Tetracycline-inducible expression of KLF4 in B-cell progenitors of transgenic mice blocks transformation by BCR-ABL and depletes leukemic pre-B cells in vivo. Collectively, our work identifies KLF4 as a putative tumor suppressor in B-cell malignancies.

1 April 2015 in Journal of Virology
Verified
Journal Article
Open access
PDF file
AKArif A. Khan
Arif A. Khan
RSRuchi Srivastava
Ruchi Srivastava
DSDoran Spencer
Doran Spencer
SGSumit Garg
Sumit Garg
DFDaniel Fremgen
Daniel Fremgen
LBLBACHIR BENMOHAMED
LBACHIR BENMOHAMED
Herpes simplex virus 1 (HSV-1) glycoprotein B (gB)-specific CD8+T cells protect mice from herpes infection and disease. However, whether and which HSV-1 gB-specific CD8+T cells play a key role in the “natural” protection seen in HSV-1-seropositive healthy asymptomatic (ASYMP) individuals (who have never had clinical herpes disease) remain to be determined. In this study, we have dissected the phenotypes and the functions of HSV-1 gB-specific CD8+T cells from HLA-A*02:01 positive, HSV-1 seropositive ASYMP and symptomatic (SYMP) individuals (with a history of numerous episodes of recurrent ocular herpes disease). We found the following. (i) Healthy ASYMP individuals maintained a significantly higher proportion of differentiated HSV-1 gB-specific effector memory CD8+T cells (TEMcells) (CD45RAlowCCR7lowCD44highCD62Llow). In contrast, SYMP patients had frequent less-differentiated central memory CD8+T cells (TCMcells) (CD45RAlowCCR7highCD44lowCD62Lhigh). (ii) ASYMP individuals had significantly higher proportions of multifunctional effector CD8+T cells which responded mainly to gB342–350and gB561–569“ASYMP” epitopes, and simultaneously produced IFN-γ, CD107a/b, granzyme B, and perforin. In contrast, effector CD8+T cells from SYMP individuals were mostly monofunctional and were directed mainly against nonoverlapping gB17–25and gB183–191“SYMP” epitopes. (iii) Immunization of an HLA-A*02:01 transgenic mouse model of ocular herpes with “ASYMP” CD8+TEMcell epitopes, but not with “SYMP” CD8+TCMcell epitopes, induced a strong CD8+T cell-dependent protective immunity against ocular herpes infection and disease. Our findings provide insights into the role of HSV-specific CD8+TEMcells in protection against herpes and should be considered in the development of an effective vaccine.IMPORTANCEA significantly higher proportion of differentiated and multifunctional HSV-1 gB-specific effector memory CD8+T cells (TEMcells) (CD45RAlowCCR7lowCD44highCD62Llow) were found in healthy ASYMP individuals who are seropositive for HSV-1 but never had any recurrent herpetic disease, while there were frequent less-differentiated and monofunctional central memory CD8+T cells (TCMcells) (CD45RAlowCCR7highCD44lowCD62Lhigh) in SYMP patients. Immunization with “ASYMP” CD8+TEMcell epitopes, but not with “SYMP” CD8+TCMcell epitopes, induced a strong protective HSV-specific CD8+T cell response in HLA-A*02:01 transgenic mice. These findings are important for the development of a safe and effective T cell-based herpes vaccine.